425: NLS Pharmaceutics and Kadimastem Advance Type 1 Diabetes Treatment with FDA Pre-IND Submission

NLS Pharmaceutics and Kadimastem, in collaboration with iTolerance, have submitted a request for a Pre-Investigational New Drug (Pre-IND) meeting with the FDA for their innovative Type 1 Diabetes treatment, iTOL102.

Summary

• NLS Pharmaceutics and Kadimastem, along with iTolerance, have submitted a request for a Pre-IND meeting with the FDA for iTOL102, a potential treatment for Type 1 Diabetes.
• iTOL102 combines allogenic human stem cell-derived pancreatic islets with an immunomodulator to potentially cure Type 1 Diabetes.
• This submission follows a successful INTERACT meeting with the FDA earlier this year.
• The collaboration is partly funded by the Israel-United States Binational Industrial Research and Development Foundation (BIRD).
• iTOL102 was evaluated at the Diabetes Research Institute (DRI) and showed functional insulin release and disease reversal in an animal model.
• NLS Pharmaceutics and Kadimastem are working to close their merger by the end of January 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the progress in developing a potential breakthrough therapy and the expected merger. However, it also acknowledges the risks and uncertainties associated with drug development and regulatory approvals.

Positives

• The submission of the Pre-IND request is a significant step towards clinical development of iTOL102.
• The combination of IsletRx and iTOL-100 has the potential to reduce or eliminate the need for life-long immunosuppression.
• iTOL102 has demonstrated functional insulin release and disease reversal in a preclinical animal model.
• The merger between NLS Pharmaceutics and Kadimastem is expected to add significant value to the combined company's pipeline.
• The collaboration is supported by the Israel-United States Binational Industrial Research and Development Foundation (BIRD).

Negatives

• The merger is subject to closing conditions, including shareholder approvals, which could delay or prevent the merger.
• The success of the treatment is not guaranteed and is subject to regulatory approvals and clinical trial outcomes.
• There are risks associated with the development of new technologies and the potential for unforeseen scientific difficulties.

Risks

• The companies may not have a successful meeting with the FDA.
• The merger may not be completed on the proposed terms or at all.
• There are risks related to obtaining shareholder approvals for the merger.
• Unexpected costs or changes to business relationships may result from the merger.
• Clinical trials may encounter delays or obstacles.
• The products may not be approved by regulatory agencies.
• The technologies may not be validated, and the methods may not be accepted by the scientific community.
• The companies may be unable to retain or attract key employees.
• Unforeseen scientific difficulties may develop with the products.
• The products may be more expensive than anticipated.
• Results in the laboratory may not translate to equally good results in real clinical settings.
• Results of preclinical studies may not correlate with the results of human clinical trials.
• The companies' patents may not be sufficient.
• The products may harm recipients.
• Changes in legislation may adversely impact the companies.
• There is a risk of loss of market share and pressure on pricing resulting from competition.

Future Outlook

The companies are optimistic about the potential of iTOL102 and the positive impact of the merger on their future growth trajectory. They are working towards closing the merger by the end of January 2025 and advancing the clinical development of iTOL102.

Management Comments

• Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, stated, 'This requested Pre-IND meeting is a crucial step in our development of iTOL 102 and towards bringing this potential breakthrough therapy to the market.'
• Dr. Anthony Japour, Chief Executive Officer of iTolerance, added, 'The submission of a request for a Pre-IND meeting with the FDA underscores our commitment to addressing the critical need for a diabetes cure with an off-the shelf human allogenic stem cell-derived pancreatic islet product together with iTolerances proprietary immunomodulator, iTOL-100, that may reduce or obviate the need for life-long immunosuppression following transplantation.'
• Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics, commented, 'We are confident that our pending merger with Kadimastem, once completed, will add significant value to the combined company's pipeline, bringing valuable assets and a promising growth trajectory.'

Industry Context

This announcement highlights the growing interest and investment in cell therapies for chronic diseases like Type 1 Diabetes. The collaboration between NLS, Kadimastem, and iTolerance reflects a trend towards combining different technologies to create more effective treatments. The focus on reducing the need for immunosuppression is a key area of innovation in the field.

Comparison to Industry Standards

• The development of allogeneic cell therapies for Type 1 Diabetes is a competitive field, with companies like Vertex Pharmaceuticals and ViaCyte also pursuing similar approaches.
• Vertex's VX-880, an allogeneic stem cell-derived islet therapy, has shown promising results in early clinical trials, but requires immunosuppression.
• ViaCyte's PEC-Direct and PEC-Encap products are also in clinical development, with the latter aiming to avoid the need for immunosuppression through encapsulation.
• iTOL102's approach of combining stem cell-derived islets with an immunomodulator to reduce or eliminate the need for immunosuppression is a key differentiator.
• The successful completion of the Pre-IND meeting and subsequent clinical trials will be crucial in determining the competitiveness of iTOL102 in the market.

Stakeholder Impact

• Shareholders of NLS Pharmaceutics and Kadimastem will be impacted by the merger and the potential success of iTOL102.
• Patients with Type 1 Diabetes could benefit from a new treatment option.
• Employees of the companies will be affected by the merger and the future direction of the combined entity.
• The collaboration could lead to new opportunities for suppliers and partners.

Next Steps

• The companies will proceed with the Pre-IND meeting with the FDA.
• They will continue to work towards closing the merger by the end of January 2025.
• They will advance the clinical development of iTOL102.

Key Dates

Keywords

Type 1 Diabetes, iTOL102, Pre-IND, FDA, IsletRx, iTOL-100, Immunomodulator, Stem Cell Therapy, Merger, Kadimastem, NLS Pharmaceutics, iTolerance